STERIS (STE) Expected to Announce Earnings on Wednesday

STERIS (NYSE:STE) will likely be posting its Q2 2026 results after the market closes on Wednesday, November 5th. Analysts expect STERIS to post earnings of $2.37 per share and revenue of $1.4303 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:00 AM ET.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period last year, the company earned $2.03 EPS. STERIS’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Trading Down 0.2%

NYSE STE opened at $235.75 on Monday. STERIS has a fifty-two week low of $200.98 and a fifty-two week high of $253.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The stock has a 50 day simple moving average of $243.79 and a two-hundred day simple moving average of $238.16. The stock has a market cap of $23.22 billion, a P/E ratio of 36.10 and a beta of 1.01.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be issued a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.1%. STERIS’s dividend payout ratio (DPR) is 38.59%.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,495 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the transaction, the director owned 705 shares in the company, valued at $170,299.80. The trade was a 83.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Renato Tamaro sold 3,204 shares of STERIS stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the completion of the sale, the vice president directly owned 7,221 shares of the company’s stock, valued at $1,799,762.04. The trade was a 30.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,868 shares of company stock valued at $4,585,389 in the last ninety days. Corporate insiders own 1.07% of the company’s stock.

Institutional Trading of STERIS

Several hedge funds have recently bought and sold shares of STE. Geneos Wealth Management Inc. grew its holdings in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the period. MUFG Securities EMEA plc bought a new stake in STERIS during the second quarter valued at about $69,000. Peapack Gladstone Financial Corp bought a new stake in STERIS during the second quarter valued at about $200,000. Evergreen Capital Management LLC grew its holdings in STERIS by 11.8% during the second quarter. Evergreen Capital Management LLC now owns 1,005 shares of the medical equipment provider’s stock valued at $241,000 after purchasing an additional 106 shares during the period. Finally, Jones Financial Companies Lllp grew its holdings in STERIS by 46.1% during the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the period. Institutional investors own 94.69% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Morgan Stanley increased their price objective on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. KeyCorp increased their price objective on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a report on Tuesday, July 22nd. Finally, Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $273.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.